Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease.  Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates.  Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.

Biotechnology

Education

Avidity

Sarah Boyce

Anneke Raney

Sarah Hudson, PhD, PMP®

Eric Mosbrooker

Marc Morris, MD JD

Teresa Brandt, PhD

Mike Flanagan

Mike MacLean

Joseph Johnston

Husam Younis

Elizabeth J Ackermann PhD

Michael MacLean

Steve Hughes

W. Michael Flanagan

John W. Wallen III

Teresa McCarthy

Arthur A. Levin

Scientific Research Team

Clinical Operations Team

Leadership Team

Accounting and Finance

Program and Alliance Management

Regulatory Affairs and Quality

Human Resources

Information Technology

Teams at Avidity